B-path
easy breath sample
to quick diagnosis
B-path
Innovative strategies for unlocking respiratory disease diagnosis
Breath pathogen detection: Establishing Exhaled Breath Aerosol (XBA) sampling for diagnosis and screening of respiratory infections
Early and accurate diagnostics are essential for controlling the spread of infectious diseases, improving patient outcomes, and reducing healthcare costs. B-Path addresses this need by developing non-invasive breath sampling devices for rapid detection of respiratory infections, aiming to transform global health diagnostics. This process will involve the development of innovative, non-invasive breath aerosol sampling devices for the early and accurate detection of pathogens like SARS-CoV-2, influenza, and tuberculosis. These scalable devices promise to enhance disease screening, control transmission, and improve global health outcomes with accessible, point-of-care solutions.
B-path
workstream & workpackages
The project aims to develop and validate non-invasive exhaled breath aerosol (XBA) sampling methods combined with multiplex molecular detection to diagnose and screen respiratory infections with pandemic potential. Regardless of symptoms, the aim of this approach is to detect multiple pathogens from a single sample and is adaptable to emerging pathogens. The goal is to enhance pandemic preparedness, improve the diagnosis of respiratory illnesses, and reduce healthcare burden by enabling more accessible and scalable testing, potentially including self-sampling and self-testing.
